LONDON, January 7, 2012 /PRNewswire/ --
A new report by visiongain, a London-based business information provider predicts the global point of care diagnostics market to be worth $34.6bn by 2021. The market generated 13.9 billion dollars in 2010 according to Point of CareDiagnostics: World Market Outlook, 2011-2021, published in December 2011.
POC diagnostics are diagnostic tests that are conducted at or near the site of patient care. The use of these tests can provide faster results, helping improve the patient management. There are already a number of POC diagnostics in the market, with many more in development. Although the POC diagnostics market is not a new segment in the IVD market, there are some sub segments that are still evolving.
Rupali Vadhera, healthcare industry reports editor says 'The point of care diagnostics are benefiting from the increasing importance of diagnostics in the healthcare systems. Although presenting an additional cost upfront, the use of diagnostic tests help in the cost management by directing the right treatment for the condition and preventing any drug associated complications as well. There are few challenges to meet, and the opportunity for growth in this market is vast. At present, there are few studies that assess the cost-effectiveness of the POC diagnostic devices; however their adoption in both professional and self testing settings has increased over recent years.'
Visiongain's research suggests that the point of care diagnostics market will benefit from the launch of new diagnostic tests as well expansion of the test menus on the marketed diagnostic devices. Any changes in the reimbursement policy will affect the growth in the market, particularly the self-testing segment. The state of each sub segment of the point of care diagnostics market is different, with different challenges and opportunities. The importance of point of care diagnostics will increase in the healthcare systems of both the developed and developing countries. Adoption the point of care tests in the developed countries will be driven by the convenience and ease of use. In the developing countries growth of point of care diagnostics will mainly be due to the lack of facilities and infrastructure for laboratory testing.
Point of care diagnostics is a well established market with significant opportunities to grow. Visiongain's analysis of the blood glucose testing, coagulation testing, cardiac marker testing and infectious diseases testing markets showed a great deal of promise in the future. This new study complements visiongain's wide range of analytical reports in healthcare and other industry areas.
To view sample pages please click on: http://www.visiongain.com/Report/739/Point-of-Care-Diagnostics-World-Market-Outlook-2012-2021
1. Executive Summary
1.1 The Point of Care (POC) Diagnostics Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. Introduction to In-Vitro Diagnostics and POC Diagnostics
2.1 What are In Vitro Diagnostic (IVD) Tests?
2.2 Classifying IVD: EDMA Classification
2.2.1 Clinical Chemistry
2.2.2 Immunochemistry
2.2.3 Haematology
2.2.4 Microbiology
2.2.5 Genetic Testing
2.3 Point of Care (POC) Diagnostics
2.3.1 Advantages and Disadvantages of POC Diagnostics
2.4 Regulation of the IVD and POC Market
2.4.1 FDA Classifications
2.4.2 FDA and CLIA Regulation of IVD and POC Tests
2.4.3 Regulation of IVD/POC Diagnostics in the EU
3. The Point of Care Diagnostics Market, 2010-2021
3.1 Point of Care Diagnostics in the IVD Market, 2010
3.2 Blood Glucose Testing is the Largest Contributor to the POC Market Sales
3.3 Self Testing Constituted the largest segment in the POC Market by the Point of Delivery, 2010
3.4 Global IVD Market Forecast, 2011-2021
3.5 Point of Care Diagnostics Market Forecast, 2011-2015
3.6 Point of Care Diagnostics Market Forecast, 2015-2021
3.7 POC Diagnostics Gaining Greater Share of the IVD Market
3.8 Clinical Diagnostics Market Forecast, 2011-2015
3.9 Clinical Diagnostics Market Forecast, 2015-2021
3.10 Sales Forecast for POC Diagnostics Market Segments, 2011-2021
3.10.1 Changing Market Shares of the Leading Segments
4. Leading National Markets for POC Diagnostics, 2010-2021
4.1 Global POC Diagnostics Market by Regions, 2010
4.1.1 Breakdown of the European Market, 2010
4.2 The US POC Diagnostics Market: Forecast and Outlook, 2011-2021
4.3 The Japanese POC Diagnostics Market: Forecast and Outlook, 2011-2021
4.4 The European POC Diagnostics Markets: Forecasts and Outlook, 2011-2021
4.4.1 Variation In the European Markets
4.5 The Asian POC Diagnostics Market: Forecast and Outlook, 2011-2021
5. Blood Glucose Testing Market, 2010-2021
5.1 Market Overview
5.2 POC Blood Glucose Testing Market in 2010
5.2.1 POC Blood Glucose Testing Market by Type of Meter
5.2.2 POC Blood Glucose Testing Market Segment by Components
5.2.3 Roche is the Market Leader in the Blood Glucose Testing Market, 2010
5.2.4 The US is the Largest Market for POC Blood Glucose Testing
5.3 Continuous Glucose Monitoring (CGM) Systems vs. Fingertip Testing
5.3.1 The CGM Pipeline
5.4 POC Blood Glucose Testing Market, 2011-2015
5.5 POC Blood Glucose Testing Market, 2015-2021
6. POC Coagulation Testing Market, 2010-2021
6.1 The POC Coagulation Testing Market in 2010
6.1.1 PT/INR Monitoring is the Largest Segment in the POC Coagulation Testing Market
6.1.2 Products Available in the POC Coagulation Testing Market, 2010
6.1.3 Roche Dominates the POC Coagulation Testing Market with CoaguChek XS System
6.2 The PT/INR POC Testing Market, 2010
6.2.1 Patient Self Testing is the Smallest, But Fastest Growing Segment
6.2.1.1 Coagulation Self-Monitoring: Reimbursement Status
6.2.2 Test Strips Generate 80% of the Sales in the PT/INR POC Testing Market
6.2.3 The US is the Largest Market for POC PT/INR Testing
6.3 POC Coagulation Testing Will Witness Strong Growth to 2015
6.4 POC Coagulation Testing Market Forecast, 2015-2021
6.5 POC Coagulation Test Systems in Development
6.5.1 Portable Coagulation Monitor, Entegrion
6.5.2 Blood Coagulation Monitor, Bio-AMD
6.5.3 Siemens-Universal Biosensors Collaboration
6.6 Drivers for Growth
7. POC Cardiac Marker Testing Market, 2010-2021
7.1 POC Testing for Cardiac Markers is Less Common than Laboratory Testing, 2010
7.2 Majority of Cardiac Marker Testing is Conducted in Critical Care Settings
7.3 Most Commonly Used Markers for POC Testing
7.4 Domination by a Few Large Diagnostic Companies
7.5 Leading Products in the POC Cardiac Marker Testing Market in 2010
7.5.1 i-STAT is the Leading Product in the Market
7.6 Cardiac Marker Testing: Huge Opportunities for Growth
7.7 POC Cardiac Marker Tests Under Development, 2011
7.7.1 Handheld Device (bioMerieux/Royal Philips Electronics)
7.7.2 QL Care Analyzer (CardioGenics)
7.8 High Entry Barriers: Challenges for the New Entrants
7.9 POC Cardiac Marker Testing Market, 2011-2015
7.10 POC Cardiac Marker Testing Market, 2015-2021
8. POC Infectious Diseases Testing Market, 2010-2021
8.1 Infectious Diseases Testing
8.2 HIV/AIDS
8.2.1 HIV POC Testing
8.2.2 The US HIV Rapid Testing Market, 2010
8.2.3 Some Other Rapid HIV Testing Kits Marketed Outside the US
8.2.4 HIV POC Tests Pipeline, 2011
8.2.5 Driving Factors for Growth of HIV Rapid Testing: Past and Future
8.3 Influenza
8.3.1 Current State of Influenza POC Testing Market
8.4 Hepatitis B & C
8.4.1 Hepatitis POC Testing Market in 2010
8.4.2 First Rapid HCV Test Approved in the US
8.4.3 Driving Factors for Growth of Hepatitis Rapid Testing
8.5 POC Infectious Disease Testing Market, 2011-2021
9. SWOT Analysis of the POC Diagnostics Market, 2011-2021
9.1 Strengths and Weaknesses of the Sector
9.1.1 Better Patient and Disease Management
9.1.2 Improved Access to Diagnostics
9.1.3 IVDs Are Vital to Clinical Decision Making
9.1.4 The Cost of POC Tests
9.1.5 Educating the End-Users
9.2 Opportunities and Threats
9.2.1 Growth of Microfluidics Use for POC Diagnostics
9.2.1.1 mChip, University of Columbia
9.2.2 Opportunities in New Areas
9.2.2.1 Diagnostics for Woundcare
9.2.2.2 Diagnostics for Syphilis
9.2.3 Expansion into Developing National Markets and Lifestyle Diseases Will Drive the Market
9.2.4 High-Entry Barriers in the POC Blood Glucose Testing Market
9.2.5 Medical Device Excise Tax: A Threat to the OEMs
10. Expert Opinion
10.1 Interview with Dr. Michael J. Lochhead, MBio Diagnostics, USA
10.1.1 On the POC Diagnostics Market
10.1.2 Opportunity for MBio Diagnostics in the POC Market
10.1.3 Opportunities and Threats in the POC Diagnostics Market
10.1.4 Growth in the POC Diagnostics Market
11. Conclusions
11.1 Overview
11.2 Commercial Drivers for the Adoption of POC Tests
11.3 Commercial Restraints in the POC Diagnostics Market
11.4 Significant Growth of POC Diagnostics Market from 2010 to 2021
11.5 Future Outlook and Concluding Remarks
Appendix A
Appendix B
Visiongain report evaluation form
Companies Listed
3M
A. Menarini
Abbott
Advanced Liquid Logic
AgaMatrix
AIMEDICS
Alere
Alfa Scientific Designs
American College of Cardiology (ACC)
American Heart Association (AHA)
ArKal Medical
Arkray
Bayer
BBI Healthcare
Bbraun
BD Biosciences
Becton Dickinson
Bio-AMD
BioHelix Corporation
bioLytical Laboratories
bioMerieux
Bionime
Bio-Rad Laboratories
Biorasis
Burnet Institute
Calypte Biomedical
CardioGenics
Center for Diseases Control and Prevention
Centers for Device and Radiological Health (CDRH)
Centers for Medicare & Medicaid Services (CMS)
Cepheid
Chembio Diagnostic Systems
CoaguSense
Daktari Diagnostics
DexCom
Diabetic Supply of Suncoast
Diagnostic Devices
Diagnostics for the Real World
DiME
Echo Therapeutics
Entegrion
Entra Health Systems
European Commission (EC)
European Diagnostics Manufacturers Association (EDMA)
EY Laboratories
Fifty50 Medical
Food and Drug Administration (FDA)
Fora Care
Gemeinsamer Bundesausschuss
Genesis Health Technology
Genzyme
German Federal Ministry of Health
Gluco Com
GluMetrics
GluSense
Health Protection Agency (HPA)
Helena Laboratories
Hemocellular Therapeutics
IME-DC
IND Diagnostics
Infopia
Instrumentation Laboratory
International Diabetes Federation
International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP)
International Technidyne Corporation
IQuum
JANT Pharmacal Corporation
Johnson & Johnson
Joint United Nations Programme on HIV/AIDS (UNAIDS)
LifeScan
LifeSign
MBio Diagnostics
Medix Biochemica
MedMira
Medtronic
Meikang Biotech
Menarini
Mendor
Meridian Bioscience
Micronics
Ministry of Health, Labor and Welfare (MHLW)
Ministry of Human Resource and Social Security (MOHRSS)
MIZUHO MEDY Company
National Health Service (NHS)
NexusDx
Nipro Diagnostics
Northwestern Global Health Foundation
Nova Biomedical
Oak Tree International Holdings
Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
OraSure Technologies
Partec
PointCare Technologies
Princeton BioMeditech Corporation
Quidel Corporation
Randox Laboratories
Remel
Roche Diagnostics
Royal Philips Electronics
Runbio Biotech Company
SA Scientific
Savyon Diagnostics
Sekisui Medical Company
Siemens Healthcare Diagnostics
Sony Corporation
Spirit Healthcare
Systagenix Wound Management
Thermofisher
Trinity Biotech
U.S. Diagnostics
Ultradian Diagnostics
Unimed International
Universal Biosensor
University of Calgary
University of Columbia
US Department of Defense (DoD)
Walmart
Wave 80 Biosciences
Werfen Group
World Health Organization (WHO)
YD Diagnostics
Ypsomed
Zyomyx
Please contact Sara Peerun for an exec summary:
Email: sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100
